biologics evaluation
Entity, reached from Hormuz.
- Evidence
- 32 documents · 4 separate publishers
- Standing
- Added automatically from coverage
- Time
- first seen 14 Apr 2026, last seen 9 Oct 2026
- Measured
- 56% of mentions say something specific about it; the rest only name it
- As of
- 10 Oct 2026
Where this comes from
- FDA · 2026-10-09 · Questions and Answers on Biosimilar Development and the BPCI Act (opens the source in a new tab)
- FDA · 2026-09-30 · Study Data Standards Resources (opens the source in a new tab)
- FDA · 2026-09-10 · FDA-TRACK: Expanded Access (Compassionate Use) Submission Data (opens the source in a new tab)
- FDA Drug News · 2026-06-13 · [APPROVAL] Real-World Evidence Submissions to the Center for Biologics Evaluation and Research & the Center for Drug Evaluation and Research (opens the source in a new tab)
What is claimed about it
Situations it is named in
Who it moves with
- co-mentioned with fda (32 documents)seen together
- co-mentioned with drug evaluation (26 documents)seen together
- co-mentioned with cber (20 documents)seen together
- co-mentioned with cder (18 documents)seen together
- co-mentioned with drug administration (18 documents)seen together
- co-mentioned with biological products (10 documents)seen together
- co-mentioned with u.s. food (10 documents)seen together
- co-mentioned with investigational new drug (9 documents)seen together
- co-mentioned with drug development (8 documents)seen together
- co-mentioned with radiological health (8 documents)seen together